Skip to main content

Table 1 Clinicopathological features and pCR

From: Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy

Variables pCR   Non-pCR   Univariate Multivariate
OR 95%CI p value OR 95%CI p value
n 25   121        
Age (mean) 55.2   53.9   1.70* 0.22–13.31 0.611 2.30* 0.16–33.38 0.534
Histology           
 NST 24 (96%) 107 (88%) 3.14 0.39–25.05 0.28    
 Others 1 (4%) 14 (12%)       
Tumour grade           
 High 15 (60%) 41 (34%) 2.93 1.21–7.09 0.017 2.43 0.83–7.40 0.107
 Low 10 (40%) 80 (66%)       
Ki67 (%, mean) 29.0   16.3   214.58* 25.26–2583.97  < 0.001    
ER           
 Positive 11 (44%) 78 (64%) 0.43 0.18–1.04 0.06 0.54 0.15–1.79 0.314
 Negative 14 (56%) 43 (36%)       
PgR           
 Positive 7 (28%) 63 (52%) 0.36 0.14–0.92 0.033    
 Negative 18 (72%) 58 (48%)       
HER2           
 Positive 14 (56%) 27 (22%) 4.43 1.80–10.88 0.001 5.22 1.86–15.53 0.002
 Negative 11 (44%) 94 (78%)       
TIL (%, mean) 42.0   22.8   8.49* 2.27–32.70 0.002 9.66* 2.17–46.07 0.003
CD8 (mean) 165.1   156.7   1.47* 0.10–16.48 0.764    
CD138 (mean) 100.9   61.3   7.00* 1.11–43.56 0.039    
  1. ER oestrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, TIL tumour-infiltrating lymphocytes, NST no special type, OR odds ratio, CI confidence interval, TIL tumour-infiltrating lymphocytes, NST no special type, OR odds ratio, CI confidence interval
  2. *Range of the odds ratio